OBJECTIVE: Recognize a rare endocrinological side effect of a drug, budesonide, which surfaced as a result of a major procedure. METHODS: We describe a patient who presented with hyperglycemic hyperosmolar state (HHS) likely as a result of the bypass of first-pass metabolism due to budesonide treatment after a transjugular intrahepatic portosystemic shunt (TIPS) procedure. RESULTS: A 62-year-old female with history of combined variable immunodeficiency complicated by colitis (managed by 9 mg budesonide by mouth daily) and refractory ascites secondary to non-cirrhotic portal hypertension (status post-TIPS 3 weeks prior) presented to the hospital with HHS. Her initial insulin requirements were high but improved after discontinuation of budesonide. She was able to be transitioned to a sliding scale and discharged on metformin. When taken orally, budesonide is subject to high first-pass metabolism resulting in minimal systemic effects. Development of HHS and dramatic insulin requirements within 3 weeks of TIPS with drastic improvement following the discontinuation of budesonide leads us to postulate that this was bypassed, leading to steroid-induced diabetes. CONCLUSION: The case beckons us to be mindful of procedures that alter drug metabolism and make necessary adjustments to prevent complications.
OBJECTIVE: Recognize a rare endocrinological side effect of a drug, budesonide, which surfaced as a result of a major procedure. METHODS: We describe a patient who presented with hyperglycemic hyperosmolar state (HHS) likely as a result of the bypass of first-pass metabolism due to budesonide treatment after a transjugular intrahepatic portosystemic shunt (TIPS) procedure. RESULTS: A 62-year-old female with history of combined variable immunodeficiency complicated by colitis (managed by 9 mg budesonide by mouth daily) and refractory ascites secondary to non-cirrhotic portal hypertension (status post-TIPS 3 weeks prior) presented to the hospital with HHS. Her initial insulin requirements were high but improved after discontinuation of budesonide. She was able to be transitioned to a sliding scale and discharged on metformin. When taken orally, budesonide is subject to high first-pass metabolism resulting in minimal systemic effects. Development of HHS and dramatic insulin requirements within 3 weeks of TIPS with drastic improvement following the discontinuation of budesonide leads us to postulate that this was bypassed, leading to steroid-induced diabetes. CONCLUSION: The case beckons us to be mindful of procedures that alter drug metabolism and make necessary adjustments to prevent complications.
Authors: Stephan Miehlke; Manuel Barreiro-de Acosta; Gerd Bouma; Daniel Carpio; Fernando Magro; Tom Moreels; Chris Probert Journal: J Gastroenterol Hepatol Date: 2018-03-30 Impact factor: 4.029
Authors: T Andus; V Gross; I Caesar; H J Schulz; H Lochs; W D Strohm; M Gierend; A Weber; K Ewe; J Schölmerich Journal: Dig Dis Sci Date: 2003-02 Impact factor: 3.199
Authors: Evan S Dellon; David A Katzka; Margaret H Collins; Sandeep K Gupta; Lan Lan; James Williams; Ikuo Hirano Journal: Clin Gastroenterol Hepatol Date: 2018-06-12 Impact factor: 11.382
Authors: Andreas Geier; Carsten Gartung; Christoph G Dietrich; Hermann E Wasmuth; Patrick Reinartz; Siegfried Matern Journal: World J Gastroenterol Date: 2003-12 Impact factor: 5.742
Authors: Eric C Swei; Anantnoor K Brar; Jonathan D Rice; Ike I Kim; Virginia M Knez; Christopher F Doe; Lisa M Forman Journal: ACG Case Rep J Date: 2022-05-04